基于分子标志的非小细胞肺癌术后复发预测专家共识
https://oss.yuaigongwu.com/pic/20230210/1675985344422598_190.jpghttps://oss.yuaigongwu.com/pic/20230210/1675985344426457_892.jpg
https://oss.yuaigongwu.com/pic/20230210/1675985344427265_425.jpg
https://oss.yuaigongwu.com/pic/20230210/1675985344427785_493.jpg
https://oss.yuaigongwu.com/pic/20230210/1675985344427265_569.jpg
https://oss.yuaigongwu.com/pic/20230210/1675985355672842_891.jpg
https://oss.yuaigongwu.com/pic/20230210/1675985355738141_931.jpg
https://oss.yuaigongwu.com/pic/20230210/1675985355809187_908.jpg
https://oss.yuaigongwu.com/pic/20230210/1675985355866624_52.jpg
https://oss.yuaigongwu.com/pic/20230210/1675985355923680_442.jpg
https://oss.yuaigongwu.com/pic/20230210/167598535600151_893.jpg
https://oss.yuaigongwu.com/pic/20230210/1675985373689119_595.jpg
https://oss.yuaigongwu.com/pic/20230210/1675985373749858_923.jpg
https://oss.yuaigongwu.com/pic/20230210/1675985373822527_479.jpg
朗迪瑞® 肺癌14基因可作为IA-IIA期R0切除的非鳞状非小细胞肺癌患者术后复发风险分层因素，同时对于NCCN分层或者传统TNM分期，联合运用朗迪瑞®风险分层更能准确进行预测复发风险，结合MRD检测，早期术后复发风险评估多了一个武器。
https://oss.yuaigongwu.com/pic/20230218/1676721178994366_110.jpg
页:
[1]